结直肠癌（CRC）是一个重要的健康问题，在挪威发病率很高。免疫反应在结直肠癌中发挥双重作用，既提供保护作用，又促进肿瘤生长。这项研究旨在提供免疫相关基因的详细筛查，并鉴定挪威人群中结直肠癌和腺瘤性息肉中的特定基因，有可能作为检测生物标志物。该研究涉及 69 名接受结肠镜检查的患者（228 个活检组织），分为结直肠癌、腺瘤性息肉和结直肠癌。息肉组和对照组。我们通过 nCounter 分析检查了 579 个免疫基因的表达，强调肿瘤与邻近非肿瘤组织中的差异表达，并针对不同患者类别进行了定量逆转录聚合酶链反应 (RT-qPCR)。主要发现包括 CXCL1、CXCL2、 CRC 组织中的 IL1B、IL6、CXCL8 (IL8)、PTGS2 和 SPP1。此外，CXCL1、CXCL2、IL6、CXCL8 和 PTGS2 在腺瘤性息肉中表现出显着的表达变化，表明它们早期参与癌变。这项研究揭示了挪威人结直肠肿瘤中独特的免疫学特征，突出显示了 CXCL1、CXCL2、IL1B、IL6、CXCL8 、PTGS2 和 SPP1 作为潜在的 CRC 生物标志物。这些发现值得进一步研究，以确认其作用并探索其在非侵入性筛查策略中的实用性。版权所有 © 2024 Omran、Tunsjø、Jahanlu、Brackmann、Bemanian 和 Sæther。

Colorectal cancer (CRC) is a significant health issue, with notable incidence rates in Norway. The immune response plays a dual role in CRC, offering both protective effects and promoting tumor growth. This research aims to provide a detailed screening of immune-related genes and identify specific genes in CRC and adenomatous polyps within the Norwegian population, potentially serving as detection biomarkers.The study involved 69 patients (228 biopsies) undergoing colonoscopy, divided into CRC, adenomatous polyps, and control groups. We examined the expression of 579 immune genes through nCounter analysis emphasizing differential expression in tumor versus adjacent non-tumorous tissue and performed quantitative reverse transcription polymerase chain reaction (RT-qPCR) across patient categories.Key findings include the elevated expression of CXCL1, CXCL2, IL1B, IL6, CXCL8 (IL8), PTGS2, and SPP1 in CRC tissues. Additionally, CXCL1, CXCL2, IL6, CXCL8, and PTGS2 showed significant expression changes in adenomatous polyps, suggesting their early involvement in carcinogenesis.This study uncovers a distinctive immunological signature in colorectal neoplasia among Norwegians, highlighting CXCL1, CXCL2, IL1B, IL6, CXCL8, PTGS2, and SPP1 as potential CRC biomarkers. These findings warrant further research to confirm their role and explore their utility in non-invasive screening strategies.Copyright © 2024 Omran, Tunsjø, Jahanlu, Brackmann, Bemanian and Sæther.